Pharmaceuticals

With $255M raised, Diagonal Therapeutics brings on a seasoned CFO to advance its novel antibody treatments for rare genetic diseases into the clinic.

Jeito Capital appoints top talent and BD partners, signaling a strategic shift in biopharma investing where deep operational expertise is now king.

A new drug, CS-1103, earns FDA Fast Track to combat fentanyl overdoses by binding and removing the opioid, a potential game-changer over naloxone.

A new 'dream team' of experts will guide AI development to create non-invasive tools for a deadly lung disease, aiming to replace painful procedures.

UK biotech Cytospire Therapeutics secures major funding to push its safer, more selective gamma delta T-cell engager into clinical trials for solid tumors.

UK biotech Cytospire secures a major Series A to bring its novel pan-gamma delta T cell engagers, targeting tough solid tumors, into clinical trials.

Hungarian pharma giant Gedeon Richter partners with chess legend Judit Polgár, using the game's strategic depth to build brand trust and inspire youth.

Beyond its first blockbuster, CRISPR Therapeutics reveals a deep pipeline for autoimmune and liver diseases, backed by a strong Q1 balance sheet.

A landmark deal brings a promising, but unapproved, therapy for a rare blinding disease to French patients via a special compassionate use program.

A strategic investment from FreeMind Investments and Daewoong Pharma validates General Proximity's novel platform for next-gen induced proximity medicines.

LANGLARA, a new Lantus biosimilar, gains FDA approval, promising more affordable diabetes care. But it faces a tough fight in a competitive market.

A German biotech's novel in vivo CAR T platform uses DNA for durable tumor control, aiming to make advanced cancer therapy an off-the-shelf medicine.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

An ultra-rare disease affects thousands, but few are diagnosed. Now, a new alliance of industry and advocates is racing to solve the diagnostic puzzle.

The biopharma firm gets a significant non-dilutive cash infusion, bolstering its finances to advance a promising oncology pipeline without equity dilution.

With backing from Eli Lilly, Cabaletta Bio's $150M financing will accelerate its potentially curative cell therapies for autoimmune diseases.

GRIN Therapeutics expands its pivotal Phase 3 study for radiprodil to Europe, fueling hope for a first-ever targeted therapy for a rare neurological disorder.

Spanish CDMO ROIS acquires a major Phoenix facility from Bristol Myers Squibb, securing US drug supply chains and expanding its global footprint.

The electric vehicle innovator plans a public debut through a SPAC deal, aiming to revolutionize the global cold-chain with its smart refrigerated trucks.

A new company emerges from Purdue Pharma's bankruptcy, owned by a non-profit and tasked with fighting the very opioid crisis its predecessor fueled.